Circular RNAs in glioblastoma

IF 3.2 3区医学 Q2 MEDICAL LABORATORY TECHNOLOGY

Clinica Chimica Acta Pub Date : 2024-10-22 DOI:10.1016/j.cca.2024.120003

Elham Ghadami , Mahjoobeh Jafari , Masoumeh Razipour , Mohaddese Maghsudlu , Mohsen Ghadami

引用次数: 0

Abstract

Glioblastoma multiforme (GBM) is the most malignant and common form of brain cancer in adults. The molecular mechanisms underlying GBM progression and resistance are complex and poorly understood. Circular RNAs (circRNAs) are a new class of non-coding RNAs formed by covalently closed loop structures with no free ends. Their circular structure makes them more stable than linear RNA and resistant to exonuclease degradation. In recent years, they have received significant attention due to their diverse functions in gene regulation and their association with various diseases, including cancer. Therefore, understanding the functions and applications of circRNAs is critical to developing targeted therapeutic interventions and advancing the field of glioblastoma cancer research. In this review, we summarized the main functions of circRNAs and their potential applications in the diagnosis, prognosis and targeted therapy of GBM.

查看原文本刊更多论文

胶质母细胞瘤中的环状 RNA。

多形性胶质母细胞瘤（GBM）是最恶性、最常见的成人脑癌。GBM进展和耐药性的分子机制十分复杂，人们对此知之甚少。环状 RNA（circRNA）是一类新的非编码 RNA，由共价封闭的环状结构形成，没有自由末端。环状结构使其比线性 RNA 更稳定，并能抵抗外切酶的降解。近年来，由于它们在基因调控中的多种功能以及与包括癌症在内的多种疾病的关联，它们受到了极大的关注。因此，了解 circRNAs 的功能和应用对于开发靶向治疗干预措施和推进胶质母细胞瘤癌症研究领域至关重要。在这篇综述中，我们总结了 circRNAs 的主要功能及其在 GBM 诊断、预后和靶向治疗中的潜在应用。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Clinica Chimica Acta 医学-医学实验技术

CiteScore

10.10

自引率

2.00%

发文量

1268

审稿时长

23 days

期刊介绍： The Official Journal of the International Federation of Clinical Chemistry and Laboratory Medicine (IFCC) Clinica Chimica Acta is a high-quality journal which publishes original Research Communications in the field of clinical chemistry and laboratory medicine, defined as the diagnostic application of chemistry, biochemistry, immunochemistry, biochemical aspects of hematology, toxicology, and molecular biology to the study of human disease in body fluids and cells. The objective of the journal is to publish novel information leading to a better understanding of biological mechanisms of human diseases, their prevention, diagnosis, and patient management. Reports of an applied clinical character are also welcome. Papers concerned with normal metabolic processes or with constituents of normal cells or body fluids, such as reports of experimental or clinical studies in animals, are only considered when they are clearly and directly relevant to human disease. Evaluation of commercial products have a low priority for publication, unless they are novel or represent a technological breakthrough. Studies dealing with effects of drugs and natural products and studies dealing with the redox status in various diseases are not within the journal''s scope. Development and evaluation of novel analytical methodologies where applicable to diagnostic clinical chemistry and laboratory medicine, including point-of-care testing, and topics on laboratory management and informatics will also be considered. Studies focused on emerging diagnostic technologies and (big) data analysis procedures including digitalization, mobile Health, and artificial Intelligence applied to Laboratory Medicine are also of interest.